Organon & Co. Common Stock (OGN)
Frequently Asked Questions About Organon & Co. Common Stock (OGN)
Can I find Organon & Co.'s investor relations information online?
Yes, Organon & Co. provides comprehensive investor relations information on its official website. This includes financial reports, stock performance, corporate governance details, and other relevant updates for shareholders and potential investors.
Does Organon & Co. have any ongoing clinical trials?
Yes, Organon & Co. has several ongoing clinical trials aimed at advancing its pipeline of products focused on women's health and related therapeutic areas. Details about specific trials can be found in the company's clinical trial registry or announcements.
Has Organon & Co. made any recent acquisitions?
As of my last knowledge update in October 2023, Organon & Co. has focused on strategic partnerships and collaborations to enhance its portfolio, though specific acquisition details may vary. For the latest information on acquisitions, it's best to refer to the company's press releases or financial disclosures.
How can I invest in Organon & Co.?
To invest in Organon & Co., you can purchase shares through a brokerage account that offers access to the New York Stock Exchange. It's essential to perform due diligence and consider market conditions before making any investment decisions.
How does Organon & Co. prioritize women's health?
Women's health is at the core of Organon & Co.'s mission, with a commitment to addressing unmet medical needs specific to women. The company invests in research and development aimed at providing innovative solutions to improve health outcomes for women and to promote health equity in care.
How does Organon & Co. support sustainability?
Organon & Co. is committed to sustainability through various initiatives aimed at reducing its environmental impact, improving supply chain efficiency, and promoting responsible corporate governance. The company strives for a healthier planet while also enhancing health outcomes.
How often does Organon & Co. report financial results?
Organon & Co. typically reports its financial results on a quarterly basis, in line with standard practices for publicly traded companies. These reports provide insights into the company's performance, financial health, and strategic direction.
What are some key products offered by Organon & Co.?
Organon & Co. markets a number of key products, including its contraceptive products, infertility treatments, and therapies for menopause. Some well-known products include Nexplanon (a contraceptive implant) and various biosimilar medications.
What are the company's future goals?
Organon & Co. aims to expand its offerings in women's health and related areas, enhance its pipeline of innovative therapies, and drive sustainable growth. The company is focused on addressing women's unmet health needs and delivering impactful solutions in healthcare.
What does Organon & Co. do?
Organon & Co. is a global healthcare company that focuses on women's health, biosimilars, and other therapeutic areas. The company develops and markets a range of medicines and innovative solutions aimed at addressing health needs throughout a woman's life cycle, including contraception, fertility, and menopause.
What impact has the COVID-19 pandemic had on Organon & Co.?
Like many companies, Organon & Co. faced challenges during the COVID-19 pandemic, affecting supply chains and healthcare access. However, the company adapted by prioritizing the health and safety of patients and employees, while also contributing to broader public health efforts.
What is the company's approach to research and development?
Organon & Co. pursues a robust approach to research and development by focusing on innovative solutions for women's health. The company invests in clinical trials and collaborations to expedite drug development and address healthcare gaps for women across the globe.
What is the company's commitment to health equity?
Organon & Co. is dedicated to promoting health equity by ensuring access to healthcare solutions for women, particularly in underserved populations. The company engages in initiatives aimed at improving education, access to care, and health outcomes for all women.
What is the significance of the name 'Organon'?
The name 'Organon' is derived from the Greek word meaning 'tool' or 'instrument.' It reflects the company's commitment to being a valuable tool in the healthcare system, particularly in the realm of women's health.
What is the stock symbol for Organon & Co.?
The stock symbol for Organon & Co. is OGN. The company is listed on the New York Stock Exchange (NYSE) under this ticker.
What therapeutic areas does Organon & Co. target?
Organon & Co. primarily focuses on women's health, but its therapeutic areas also include biosimilars and other specialized treatments. This broad focus allows the company to address diverse health needs that affect women and patients globally.
When was Organon & Co. founded?
Organon & Co. was established as a standalone company on June 3, 2021, when it spun off from Merck & Co., marking its journey to focus specifically on women's health and related therapeutic areas.
Where is Organon & Co. headquartered?
Organon & Co. is headquartered in Jersey City, New Jersey, USA. The company's location provides access to a vibrant life sciences ecosystem and positions it strategically for global operations.
Who is the CEO of Organon & Co.?
As of October 2023, the CEO of Organon & Co. is Prakash Chandran, who was appointed to lead the company following its separation from Merck. Under his leadership, the company continues to drive its vision to support women's health initiatives.
What is the current price of Organon & Co. Common Stock?
The current price of Organon & Co. Common Stock is 14.72
When was Organon & Co. Common Stock last traded?
The last trade of Organon & Co. Common Stock was at 6:30 pm EDT on April 2nd, 2025